Faculty profile

David Allan

Back to faculty

Associate ProfessorDepartment of MedicineUniversity of Ottawa

David Allan

Associate Professor

Department of Medicine

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
20 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2008.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Latest papers

Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis.
Transplantation and cellular therapy · 2026
Factors Associated With Prolonged Inpatient Stay in Patients Undergoing Outpatient Allogeneic Stem Cell Transplantation.
Transplantation and cellular therapy · 2026
Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models.
Transplantation and cellular therapy · 2026 · senior author

All 62 publications

Latest funding

Platelet Transfusions in Hematopoietic Stem Cell Transplantation - The PATH Phase III Trial
CIHR · 2019 · Co-investigator
$1,507,050
Molecular Targeting of Human Acute Myeloid Leukemia and Bone Marrow Regeneration
CIHR · 2017 · Co-investigator
$4,162,215
Endothelial Progenitor Cell Exosomes and MicroRNA Transfer as Therapy for Acute Kidney Injury
CIHR · 2017 · Co-investigator
$742,050

All 11 grants and awards

62 publications.

Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis.

Abduallah Y, Allan D, Atkins H, Bredeson C, Kekre N, Kennah M, Masurekar A, Thyagu S, Nampoothiri RV

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.09.001 PMID: 42700928

Factors Associated With Prolonged Inpatient Stay in Patients Undergoing Outpatient Allogeneic Stem Cell Transplantation.

Koo E, Prince C, Allan D, Atkins H, Bredeson C, Kekre N, Kennah M, Masurekar A, Thyagu S, Vasudevan Nampoothiri R

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.01.036 PMID: 41690552

Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models.

Masurekar AN, Burkett KM, Rahgozar A, Walter RB, Othus M, Abrol K, Mortezaagha P, Thyagu S, Nampoothiri RV, Kennah M, Kekre N, Giguere P, Abduallah Y, Atkins H, Cieniak C, Berardi P, Ramsay T, Mallick R, Carrier M, Bredeson C, Allan D

Transplantation and cellular therapy2026Senior author

DOI: 10.1016/j.jtct.2025.12.996 PMID: 41482160

How does a national blood operator detect early infectious disease signals affecting blood and cellular therapy product safety and sufficiency?

Bruneau L, Charlton CL, Ramirez-Arcos S, Kumaran D, Allan D, Norman O, Seftel M, Bloch EM, Pambrun C, O'Brien SF, Cranney C, Drews SJ

Transfusion2026

DOI: 10.1111/trf.70388 PMID: 42762172

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy

Buchan CA, Agbayani G, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G

Transplantation and Cellular Therapy20263 citations

DOI: 10.1016/j.jtct.2025.10.037

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Bhella S, Agbayani G, Hueniken K, Vijenthira A, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Hosseini-Moghaddam SM

Blood advances2026

DOI: 10.1182/bloodadvances.2025018117

Cell Therapy Transplant Canada (CTTC) Consensus-Based Review for the Use of Supportive Care and Topical Therapies for Chronic Graft-Versus-Host Disease

Lepic K, Aziz J, Popradi G, Lemieux C, White J, Maier S, Elemary M, Schultz K, Paulson K, Vasudevan Nampoothiri R

Current Oncology2026

DOI: 10.3390/curroncol33090548

Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (ATG) Based GVHD Prophylaxis.

Dhir V, Prince C, Allan D, Atkins H, Bredeson C, Kekre N, Kennah M, Masurekar A, Vasudevan Nampoothiri R

European journal of haematology2025

DOI: 10.1111/ejh.14380 PMID: 39757868

Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation.

Beland B, Storek J, Quartermain L, Hahn C, Pringle CE, Bourque PR, Kennah M, Kekre N, Bredeson C, Allan D, Jamani K, White C, Atkins H

Annals of clinical and translational neurology2025

DOI: 10.1002/acn3.52246 PMID: 39737848

Analysis of HLA matching between deceased organ donors and cord blood units from a National Bank Network as a basis for potential platforms for chimerism-based immune tolerance after solid organ transplantation.

Crocchiolo R, Lombardini L, Sacchi N, Lombardi I, Blake J, Allan D, Sobh M, Puoti F, Trapani S, Gallina AM, Sacchi M, Pupella S, Bergamaschi P, Rossini S, Cardillo M

Blood transfusion = Trasfusione del sangue2025

DOI: 10.2450/bloodtransfus.759 PMID: 38949850

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

David Allan

Research

Latest papers

Latest funding

Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis.

Factors Associated With Prolonged Inpatient Stay in Patients Undergoing Outpatient Allogeneic Stem Cell Transplantation.

Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models.

How does a national blood operator detect early infectious disease signals affecting blood and cellular therapy product safety and sufficiency?

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Cell Therapy Transplant Canada (CTTC) Consensus-Based Review for the Use of Supportive Care and Topical Therapies for Chronic Graft-Versus-Host Disease

Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (ATG) Based GVHD Prophylaxis.

Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation.

Analysis of HLA matching between deceased organ donors and cord blood units from a National Bank Network as a basis for potential platforms for chimerism-based immune tolerance after solid organ transplantation.

Frequent collaborators

Christopher Bredeson

Natasha Kekre

Lothar Huebsch

Harold Atkins

Mitchell Sabloff

Jason Tay

Alan Tinmouth

Michael Kennah

Dean Fergusson

Dawn Maze

Alissa Visram

Lisheng Wang

Curtis Cooper

Amaris Karin Balitsky

Kylie Lepic

Maryam Vaseghi-Shanjani

Michael Sebag

Arleigh McCurdy

Nicolas Pineault

Jacob Karsh

Stephen Betschel

Robert Smith

Michael Chu

Sandra Ramirez-Arcos

Donna Reece

Amit Bar-Or

Markus Selzner